Drugs / Nerofe
Nerofe
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05661201 | Apr 2023 → Jan 2027 expected | cancer | Georgetown University | Recruiting | No outcome recorded |
| Phase 1 | NCT04365179 | Jun 2020 → Jun 2025 overdue | acute myeloid leukemia, myelodysplastic syndrome | Immune System Key Ltd | Recruiting | No outcome recorded |
| Phase 1 | NCT01690741 | Dec 2013 → Dec 2017 | cancer | Immune System Key Ltd | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03634150 | Sep 2018 → Apr 2020 | ovarian cancer, triple-negative breast carcinoma | Immune System Key Ltd | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 21 trial | ||||||
| Phase 2 | NCT03059615 | Oct 2018 → Jul 2020 | acute myeloid leukemia, myelodysplastic syndrome | Immune System Key Ltd | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NEROFE | “Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced MDS and AML” NCT04365179 ↗ |
| Known as | Tcapf | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297308 ↗ |
| Known as | Tumor-cells apoptosis factor | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297308 ↗ |
| Action | Activate | “Binding Nerofe to the T1/ST2 receptor caused a rapid activation both of Caspase 8 and Bcl-2 mediated downstream in proliferating cancer cells.” NCT03059615 ↗ |
| Modality | Peptide | “anti-cancer peptide Nerofe” NCT01690741 ↗ |
| Route | Intravenous | “Nerofe administered intravenously 3x/week” NCT01690741 ↗ |